Image de couverture de livre

Effect of Hepatic and Renal Impairment on the Pharmacokinetics of Dersimelagon (MT‐7117), an Oral Melanocortin‐1 Receptor Agonist

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Akihito Ogasawara, Ryosuke Ide, Shinsuke Inoue, Renli Teng, Atsuhiro Kawaguchi
Format:	Artículo Open Access
Publié:	Wiley 2024
Sujets:	Clinical Pharmacology in Drug Development
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Assessment of Potential Drug–Drug Interactions for Novel Oral Melanocortin‐1 Receptor Agonist Dersimelagon
par: Akihito Ogasawara, et autres
Publié: (2025)

Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Pritelivir and Its Metabolites
par: Katharina Erb‐Zohar, et autres
Publié: (2024)

Bioavailability, Metabolism, and Excretion of [14C]‐Tazemetostat in Patients With B‐Cell Lymphomas or Advanced Solid Tumors
par: Yingxue Chen, et autres
Publié: (2025)

Effect of Cytochrome P450 3A Inhibition and Induction by Itraconazole and Rifampin on Tazemetostat Pharmacokinetics in Patients With Advanced Malignancies
par: Yingxue Chen, et autres
Publié: (2025)

Effect of Renal Impairment on the Pharmacokinetics and Safety of Doxecitine and Doxribtimine: A Single‐Dose Phase 1 Study
par: Aravind Mittur, et autres
Publié: (2026)

A Phase 1, Open‐Label, Single‐Dose Study of the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib, an FGFR Inhibitor
par: Wei Zhu, et autres
Publié: (2026)

A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of TPN171 (a PDE5 Inhibitor) in Adults with Renal Impairment
par: Ping Fu, et autres
Publié: (2025)

First‐in‐Human Study of Merotocin, a Short‐Acting Peptidic Oxytocin Receptor Agonist for Lactation Support
par: Yu Bagger, et autres
Publié: (2025)

Pharmacokinetics and Bioequivalence of 2 Oral Formulations of Vildagliptin in Healthy Chinese Subjects
par: Mengli Tian, et autres
Publié: (2024)

Pharmacokinetics, Receptor Occupancy, and Pharmacodynamics of Obexelimab Following Intravenous Administration in Adult Healthy Volunteers and in Patients With Rheumatoid Arthritis
par: Xiaodong Wang, et autres
Publié: (2025)

Pharmacokinetic Profile and Comparative Bioavailability of an Oral Fixed‐Dose Combination of Metformin and Acetylsalicylic Acid (Aspirin)
par: Lourdes Garza‐Ocañas, et autres
Publié: (2024)

Population Pharmacokinetics Modeling and Simulation of Deutenzalutamide, A Novel Androgen Receptor Antagonist, in Patients With Metastatic Castration‐Resistant Prostate Cancer
par: Yixian Liu, et autres
Publié: (2024)

Pharmacokinetics and Safety of Single‐Dose Apraglutide in Individuals with Normal and Impaired Hepatic Function: A Phase 1, Open‐Label Trial
par: Gerard Greig, et autres
Publié: (2026)

Results from a Phase 1 Study Assessing the Pharmacokinetics of the Aldosterone Synthase Inhibitor Baxdrostat in Participants with Varying Degrees of Renal Function
par: Mason W. Freeman, et autres
Publié: (2024)

Pharmacokinetic Interaction Among Amlodipine, Losartan, and Chlorthalidone after a Single Oral Administration in Healthy Male Subjects
par: Seol Ju Moon, et autres
Publié: (2026)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Neonatal Fc Receptor Inhibitor Rozanolixizumab: An Ethnic Sensitivity Study in Healthy Japanese, Chinese, and White Participants
par: Assem el Baghdady, et autres
Publié: (2024)

Pharmacokinetics of Fipaxalparant, a Small‐Molecule Selective Negative Allosteric Modulator of Lysophosphatidic Acid Receptor 1, and the Effect of Food in Healthy Volunteers
par: Yang Song, et autres
Publié: (2024)

Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a BTLA Agonist Antibody (Venanprubart) in Healthy Participants, Patients with Systemic Lupus Erythematosus, and Patients with Psoriasis: Results From Three Phase 1 Studies
par: Andrew C. Vendel, et autres
Publié: (2026)

Pharmacokinetics of Nitazoxanide Dry Suspensions After Single Oral Doses in Healthy Subjects: Food Effects Evaluation and Bioequivalence Study
par: Chenning Zhang, et autres
Publié: (2024)

Pharmacokinetics, Tolerability, and Biomarker Profile of the Neurokinin 3 Receptor Antagonist Fezolinetant in Healthy Japanese Individuals: A 2‐Part, Randomized, Phase 1 Study
par: Akira Koibuchi, et autres
Publié: (2025)

Pharmacokinetics, Bioequivalence, and Safety Evaluation of Two Oral Formulations of Calcium Dobesilate Capsules in Healthy Chinese Volunteers Under Fasting and Fed Conditions
par: Yanrong Wang, et autres
Publié: (2024)

Integrating Pharmacogenomic Insights in GLP‐1 Receptor Agonist Therapy: Direct GLP1R and ARRB1 Variants and Indirect CYP2D6 Influences in Personalized Obesity Management
par: Navodi Sandamini Jayathilaka, et autres
Publié: (2025)

Effect of Carbamazepine on the Pharmacokinetics of Erdafitinib in Healthy Participants
par: Pharavee Jaiprasart, et autres
Publié: (2024)

Effect of Strong CYP3A4 Inhibition, CYP3A4 Induction, and OATP1B1/3 Inhibition on the Pharmacokinetics of a Single Oral Dose of Sotorasib
par: Panli Cardona, et autres
Publié: (2024)

Correction to “Preclinical and Phase 1 Assessment of Antisense Oligonucleotide Bepirovirsenin Hepatitis B Virus–Transgenic Mice and Healthy Human Volunteers: Support for Clinical Dose Selection and Evaluation of Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses”
Publié: (2025)

The Triple‐Agonist Revolution: Retatrutide and the Paradigm Shift in Multi‐Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities
par: Nila Ganamurali, et autres
Publié: (2026)

Pharmacokinetics and Bioequivalence of Vardenafil Hydrochloride in Healthy Chinese Volunteers
par: Sheng He, et autres
Publié: (2024)

Population Pharmacokinetics of Naloxegol in Pediatric Subjects Receiving Opioids
par: Matthew W. Hruska, et autres
Publié: (2024)

Phase 1, Single‐Center, Double‐Blind, Randomized, Placebo‐Controlled Studies of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of the Sirtuin 6 Activator SP‐624 in Healthy Adults
par: Greg Rigdon, et autres
Publié: (2024)

Safety and Pharmacokinetics of Quizartinib Combination Therapy With Standard Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia: Results from Two Phase 1 Trials in Japan and China
par: Junyuan Qi, et autres
Publié: (2024)

Pharmacokinetics, Safety, and Tolerability of Cedirogant in Healthy Japanese and Chinese Adults
par: Mohamed‐Eslam F Mohamed, et autres
Publié: (2024)

Bioequivalence and Pharmacokinetic Evaluation of Regorafenib Tablets in Healthy Chinese Volunteers
par: Zhaoyu Wang, et autres
Publié: (2024)

Comparison of the Pharmacokinetics of Three Budesonide Formulations in Healthy Chinese Subjects
par: Tengrui Yin, et autres
Publié: (2025)

Assessment of Pharmacokinetic Drug Interaction of Asciminib with Atorvastatin in Healthy Participants
par: Matthias Hoch, et autres
Publié: (2025)

Intravenous Ganaxolone: Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability in Healthy Adults
par: Maciej Gasior, et autres
Publié: (2024)

Effects of Cedirogant on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates
par: Ronilda D'Cunha, et autres
Publié: (2026)

Pharmacokinetics, Bioequivalence, and Safety of Levothyroxine Sodium Tablets in Healthy Chinese Subjects
par: Juan Jin, et autres
Publié: (2025)

Population Pharmacokinetics of Butylphthalide Injection in Elderly Chinese Patients With Ischemic Stroke
par: Shu‐Xian Lyu, et autres
Publié: (2025)

Pharmacokinetics, Bioequivalence, and Safety of Bromocriptine Mesylate Tablets in Healthy Chinese Subjects
par: Huan Song, et autres
Publié: (2025)

Effect of a High‐Fat Meal on the Pharmacokinetics of an Immediate Release Atogepant Tablet
par: Ramesh R. Boinpally, et autres
Publié: (2024)